Project Grant HT94252410335

This Project Grant award of $680,433 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research at the University of California, San Francisco (UCSF) to improve prognostic estimation and understanding of prostate cancer heterogeneity and biology. The key goals are to: 1) understand the relationships between established genomic tests and pathology artificial intelligence (PAI) algorithms in predicting outcomes after...

This Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), supports a $920,262 longitudinal study on the role of androgen deprivation therapy in depression among prostate cancer patients. The research will be conducted by McMaster University, a private non-profit university in Canada, over the period from May 2024 to May 2027. This award reflects the program's focus on innovative, high-impact biomedical...

The National Cancer Institute (NCI) awarded a $386,866 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Regents of the University of Michigan to develop individualized estimates of treatment benefit from hormone therapy for men with prostate cancer. The project aims to integrate models for other-cause mortality risk, distant metastases, and prostate cancer-specific mortality to provide personalized estimates of treatment outcomes, and to develop a web...

The Bronx Veterans Medical Research Foundation, Inc. (BVMRF) was awarded a $339,855 federal Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant funding supports a 3-year research project titled "DATA SCIENCE APPROACHES TO PREDICT AND UNDERSTAND SIDE EFFECTS OF ANDROGEN DEPRIVATION THERAPY IN VETERANS WITH PROSTATE CANCER UNDERGOING LONG-TERM TREATMENT." This research aims to utilize data science methods to...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is focused on integrating radiologist insights to develop advanced AI-assisted systems for interpreting prostate MRI scans. The $245,087 award will fund a collaboration between Memorial Sloan Kettering (MSK) radiologists and researchers at the University of Delaware (UD) to achieve the following key objectives: Curate a comprehensive dataset by annotating...

This National Cancer Institute project grant of $808,336 provides funding from September 2022 through August 2025 to investigate the effects of androgen receptor antagonism on human T cell function. The University of Portland will determine how androgen deprivation therapies used in prostate cancer treatment impact the adaptive immune response. Researchers will study the impact of the clinically relevant androgen receptor antagonist enzalutamide on T cells isolated from healthy volunteers in...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Yale University totals $167,500 and will be executed from September 2023 through August 2025. The primary objectives are to: Develop deep neural network-based emulation analysis methods and software to objectively quantify the relative effectiveness of drugs, devices, and treatment procedures on cancer prognosis, especially when randomized clinical trials are not feasible. The...

The National Cancer Institute (NCI) awarded a $602,361 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Yale University to develop deep learning-based models for personalized treatment planning of prostate cancer patients receiving 177Lu-PSMA radiopharmaceutical therapy (RPT). The project aims to leverage PSMA-PET and 177Lu-PSMA SPECT imaging data collected during RPT to build predictive dosimetry models that can enable personalized dose calculations and optimize...

This federal Project Grant award of $644,622 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) aims to enhance radioligand therapy for prostate cancer through the development of biomarker and dosimetry-guided personalized treatment approaches. The key objectives are to: 1) develop a novel method for bone marrow dosimetry using macro/micro Monte Carlo modeling, 2) build predictive models to estimate absorbed radiation doses from pre-therapy PET...

This National Cancer Institute (NCI) Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program will fund a $762,258 cluster randomized controlled trial at Cedars-Sinai Medical Center. The trial aims to test whether providing natural language processing (NLP) and artificial intelligence (AI)-based feedback to patients and physicians on key treatment tradeoffs discussed during prostate cancer consultations can improve patient decision making and physician risk...